135 related articles for article (PubMed ID: 37381749)
1. Ursodeoxycholic acid administration did not reduce susceptibility to SARS-CoV-2 infection in children.
Liu T; Wang JS
Liver Int; 2023 Sep; 43(9):1950-1954. PubMed ID: 37381749
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease.
Li Y; Zhu N; Cui X; Lin Y; Li X
Front Cell Infect Microbiol; 2023; 13():1178590. PubMed ID: 37207192
[TBL] [Abstract][Full Text] [Related]
3. Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in patients with liver transplantation: a multicenter retrospective cohort study.
Hu L; Zhang H; Huang C; Shen T; Feng Z; Mu F; Xu L; Lin Y; Yue C; Guo K; Tian M; Shi J; Zhang C; Wen P; Cao S; Wang Y; Zhang J; Shi X; Wang Z; He Y; Zhang X; Liu X; Lv Y; Liu Z; Guo W; Wang B
QJM; 2024 Jun; 117(5):339-347. PubMed ID: 37950449
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort.
Gao H; Wang J; Zheng X; Pei X; Zheng Y; Zhai W; Zhang R; Chen X; Ma Q; Wei J; Yang D; Pang A; He Y; Feng S; Cao Y; Jiang E
Front Cell Infect Microbiol; 2024; 14():1324019. PubMed ID: 38505288
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin-converting enzyme 2.
Lee K; Na Y; Kim M; Lee D; Choi J; Kim G; Kim MS
Pharmacol Res Perspect; 2024 Apr; 12(2):e1194. PubMed ID: 38573021
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis.
John BV; Bastaich D; Webb G; Brevini T; Moon A; Ferreira RD; Chin AM; Kaplan DE; Taddei TH; Serper M; Mahmud N; Deng Y; Chao HH; Sampaziotis F; Dahman B
J Intern Med; 2023 May; 293(5):636-647. PubMed ID: 37018129
[TBL] [Abstract][Full Text] [Related]
7. Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-word setting.
Corpechot C; Verdoux M; Frank-Soltysiak M; Duclos-Vallée JC; Grimaldi L
J Med Virol; 2024 Jan; 96(1):e29418. PubMed ID: 38240338
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients.
Colapietro F; Angelotti G; Masetti C; Shiffer D; Pugliese N; De Nicola S; Carella F; Desai A; Ormas M; Calatroni M; Omodei P; Ciccarelli M; Aliberti S; Reggiani F; Bartoletti M; Cecconi M; Lleo A; Aghemo A; Voza A
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632080
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid does not affect the clinical outcome of SARS-CoV-2 infection: A retrospective study of propensity score-matched cohorts.
Marrone G; Covino M; Merra G; Piccioni A; Amodeo A; Novelli A; Murri R; Pompili M; Gasbarrini A; Franceschi F
Liver Int; 2024 Jan; 44(1):83-92. PubMed ID: 37735968
[TBL] [Abstract][Full Text] [Related]
10. Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis.
Rodal Canales FJ; Pérez-Campos Mayoral L; Hernández-Huerta MT; Sánchez Navarro LM; Matias-Cervantes CA; Martínez Cruz M; Cruz Parada E; Zenteno E; Ramos-Martínez EG; Pérez-Campos Mayoral E; Romero Díaz C; Pérez-Campos E
Sci Rep; 2021 Nov; 11(1):22288. PubMed ID: 34782703
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells.
Thuy PX; Bao TDD; Moon EY
Biomed Pharmacother; 2022 Jun; 150():113021. PubMed ID: 35658221
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features of children and their family members with family clusters of SARS-CoV-2 Omicron variant infection in Shanghai, China: an analysis of 380 cases].
Bian XL; Guo Z; Zhang K; Li MC; Wu ZM; Jiang Q; Guo MM; Fan SN; Chen JJ; Hui L; Zheng F; Zhang JP
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Oct; 24(10):1085-1091. PubMed ID: 36305107
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features of 19 children infected with the Omicron variant of severe acute respiratory syndrome coronavirus 2 in Hangzhou, China].
Qi ZH; Bei ZF; Teng S; Wang HP; Li W; Zhao SY; Liu SR
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Oct; 24(10):1092-1097. PubMed ID: 36305108
[TBL] [Abstract][Full Text] [Related]
14. Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children.
Lykavieris P; Ducot B; Lachaux A; Dabadie A; Broué P; Sarles J; Bernard O; Jacquemin E
J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):623-9. PubMed ID: 18955864
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological features and viral shedding in children with SARS-CoV-2 infection.
Hua CZ; Miao ZP; Zheng JS; Huang Q; Sun QF; Lu HP; Su FF; Wang WH; Huang LP; Chen DQ; Xu ZW; Ji LD; Zhang HP; Yang XW; Li MH; Mao YY; Ying MZ; Ye S; Shu Q; Chen EF; Liang JF; Wang W; Chen ZM; Li W; Fu JF
J Med Virol; 2020 Nov; 92(11):2804-2812. PubMed ID: 32542750
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
[TBL] [Abstract][Full Text] [Related]
18. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children.
Vajro P; Franzese A; Valerio G; Iannucci MP; Aragione N
J Pediatr; 2000 Jun; 136(6):739-43. PubMed ID: 10839869
[TBL] [Abstract][Full Text] [Related]
19. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study.
Li F; Li YY; Liu MJ; Fang LQ; Dean NE; Wong GWK; Yang XB; Longini I; Halloran ME; Wang HJ; Liu PL; Pang YH; Yan YQ; Liu S; Xia W; Lu XX; Liu Q; Yang Y; Xu SQ
Lancet Infect Dis; 2021 May; 21(5):617-628. PubMed ID: 33476567
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
